deep brain stimulation Archive

September 14, 2023

Study suggests way to relieve cognitive deficits caused by Parkinson’s disease

Vanderbilt research raises the possibility of using DBS to slow the decline of cognitive function, a major source of disability, diminished quality of life, and death in more than three-quarters of patients with Parkinson’s disease.

By Bill Snyder
photo of David Charles and Mallory Hacker
June 30, 2020

Pilot study suggests Parkinson’s disease progression can be slowed

A pair of ultra-thin electrodes surgically implanted deep into the brain might slow the progression of Parkinson’s disease, according to five-year outcomes from a 30-patient randomized clinical trial conducted by investigators at Vanderbilt University Medical Center.

By Paul Govern
December 6, 2018

Neuromodulation Society honors Hacker’s Parkinson’s research

Mallory Hacker, PhD, research assistant professor of Neurology, is the 2019 recipient of the Kumar New Investigator Award from the North American Neuromodulation Society.

By Tom Wilemon
September 1, 2016

Trial to test whether DBS slows Parkinson’s progression

A consortium led by Vanderbilt University Medical Center (VUMC) researchers has received funding as it makes plans for a multicenter trial that could determine whether deep brain stimulation (DBS) slows the progression of Parkinson’s disease in early-stage patients.

By Tom Wilemon
October 22, 2015

Neimat: Emotional disturbance is an overlooked symptom of Parkinson’s

Despite benefiting from dramatic improvements in movement after deep brain stimulation surgery, patients with Parkinson’s disease can be inadequately served when physicians and researchers focus only on its motor manifestations, says a Vanderbilt neurosurgeon.

By Tom Wilemon
April 3, 2014

DBS for Parkinson’s trial moves to next level

A long-term Vanderbilt University Medical Center study of deep brain stimulation (DBS) in early-stage Parkinson’s disease has received approval from the Food and Drug Administration (FDA) to continue in a pivotal, phase III, large-scale safety and efficacy trial.

By VUMC News and Communications